{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:53:40Z","timestamp":1776758020327,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,21]]},"DOI":"10.7759\/cureus.107436","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:25:58Z","timestamp":1776756358000},"source":"Crossref","is-referenced-by-count":0,"title":["Controlled Maxillofacial Administration of Levodopa in a Patient With Parkinson\u2019s Disease: A First-in-Human 24-Hour Follow-Up Study"],"prefix":"10.7759","author":[{"given":"Suresh  C","family":"Thirunavukarasu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B B V","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devi","family":"Varadharaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Durairaj","family":"Arumugam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayasri","family":"Poyyadhappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepika","family":"Moorthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simulia Dhinju","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jishnu","family":"Sudhakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hridwik Adiyeri","family":"Janardhanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anoop","family":"UR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00769-7","article-title":"Improving the delivery of levodopa in Parkinson's disease: a review of approved and emerging therapies","volume":"34","author":"Urso D","year":"2020","unstructured":"Urso D, Chaudhuri KR, Qamar MA, Jenner P. Improving the delivery of levodopa in Parkinson's disease: a review of approved and emerging therapies. CNS Drugs. 2020, 34:1149-63. 10.1007\/s40263-020-00769-7","journal-title":"CNS Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0386-8","article-title":"Novel levodopa formulations for Parkinson's disease","volume":"30","author":"Freitas ME","year":"2016","unstructured":"Freitas ME, Ruiz-Lopez M, Fox SH. Novel levodopa formulations for Parkinson's disease. CNS Drugs. 2016, 30:1079-95. 10.1007\/s40263-016-0386-8","journal-title":"CNS Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2014.877840","article-title":"Novel levodopa formulations in the treatment of Parkinson's disease","volume":"14","author":"Pilleri M","year":"2014","unstructured":"Pilleri M, Antonini A. Novel levodopa formulations in the treatment of Parkinson's disease. Expert Rev Neurother. 2014, 14:143-9. 10.1586\/14737175.2014.877840","journal-title":"Expert Rev Neurother"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2025.2535177","article-title":"The on-going quest for a long-acting oral form of levodopa","volume":"21","author":"Teil M","year":"2025","unstructured":"Teil M, Al-Kassmy J, Alsalmi M, Al-Rawahi B, Huot P. The on-going quest for a long-acting oral form of levodopa. Expert Opin Drug Metab Toxicol. 2025, 21:1049-58. 10.1080\/17425255.2025.2535177","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0336-5","article-title":"Levodopa-carbidopa intestinal gel in patients with Parkinson's disease: a systematic review","volume":"30","author":"Wirdefeldt K","year":"2016","unstructured":"Wirdefeldt K, Odin P, Nyholm D. Levodopa-carbidopa intestinal gel in patients with Parkinson's disease: a systematic review. CNS Drugs. 2016, 30:381-404. 10.1007\/s40263-016-0336-5","journal-title":"CNS Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70293-X","article-title":"Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study","volume":"13","author":"Olanow CW","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, et al.. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014, 13:141-9. 10.1016\/S1474-4422(13)70293-X","journal-title":"Lancet Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319857617","article-title":"Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease","volume":"10","author":"Luinstra M","year":"2019","unstructured":"Luinstra M, Rutgers W, van Laar T, et al.. Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease. Ther Adv Chronic Dis. 2019, 10:2040622319857617. 10.1177\/2040622319857617","journal-title":"Ther Adv Chronic Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.12.012","article-title":"Inhaled levodopa in Parkinson's disease patients with OFF periods: a randomized 12-month pulmonary safety study","volume":"71","author":"Grosset DG","year":"2020","unstructured":"Grosset DG, Dhall R, Gurevich T, et al.. Inhaled levodopa in Parkinson's disease patients with OFF periods: a randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020, 71:4-10. 10.1016\/j.parkreldis.2019.12.012","journal-title":"Parkinsonism Relat Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-023-02636-3","article-title":"Inhaled levodopa for threatening impending OFF episodes in managing Parkinson's disease","volume":"130","author":"Jost WH","year":"2023","unstructured":"Jost WH, Kulisevsky J, LeWitt PA. Inhaled levodopa for threatening impending OFF episodes in managing Parkinson's disease. J Neural Transm (Vienna). 2023, 130:821-6. 10.1007\/s00702-023-02636-3","journal-title":"J Neural Transm (Vienna)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.14161","article-title":"Continuous subcutaneous foslevodopa-foscarbidopa in Parkinson's disease: a mini-review of current scope and future outlook","volume":"11","author":"Aubignat M","year":"2024","unstructured":"Aubignat M, Tir M. Continuous subcutaneous foslevodopa-foscarbidopa in Parkinson's disease: a mini-review of current scope and future outlook. Mov Disord Clin Pract. 2024, 11:1188-94. 10.1002\/mdc3.14161","journal-title":"Mov Disord Clin Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-025-01179-3","article-title":"Foslevodopa\/foscarbidopa: a review in advanced Parkinson's disease","volume":"39","author":"Blair HA","year":"2025","unstructured":"Blair HA. Foslevodopa\/foscarbidopa: a review in advanced Parkinson's disease. CNS Drugs. 2025, 39:621-32. 10.1007\/s40263-025-01179-3","journal-title":"CNS Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"Soileau MJ","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, et al.. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022, 21:1099-109. 10.1016\/S1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjinnov-2019-000393","article-title":"New technique and device for controlled and continuous drug delivery into the brain: a proof-of-concept study","volume":"7","author":"U R Anoop","year":"2021","unstructured":"U R Anoop, Verma K. New technique and device for controlled and continuous drug delivery into the brain: a proof-of-concept study. BMJ Innovations. 2021, 7:470-77. 10.1136\/bmjinnov-2019-000393","journal-title":"BMJ Innovations"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.1c00030","article-title":"SARS-CoV-2: the road less traveled - from the respiratory mucosa to the brain","volume":"6","author":"Arunachalam JP","year":"2021","unstructured":"Arunachalam JP, U R A, Verma K, Rajendran R, Chidambaram S. SARS-CoV-2: the road less traveled - from the respiratory mucosa to the brain. ACS Omega. 2021, 6:7068-72. 10.1021\/acsomega.1c00030","journal-title":"ACS Omega"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.3c00184","article-title":"Protein drug delivery using a novel maxillofacial technique targeting the visual pathway in the brain, the optic nerve, and the retina","volume":"14","author":"Rajendran R","year":"2023","unstructured":"Rajendran R, Arunachalam JP, Chidambaram S, et al.. Protein drug delivery using a novel maxillofacial technique targeting the visual pathway in the brain, the optic nerve, and the retina. ACS Chem Neurosci. 2023, 14:3368-84. 10.1021\/acschemneuro.3c00184","journal-title":"ACS Chem Neurosci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48011","article-title":"The administration of levodopa in a patient with Parkinson\u2019s disease using a novel maxillofacial route: a first-in-human report","volume":"15","author":"Thirunavukarasu S","year":"2023","unstructured":"Thirunavukarasu S, Ramanan BB, Suresh SK, et al.. The administration of levodopa in a patient with Parkinson\u2019s disease using a novel maxillofacial route: a first-in-human report. Cureus. 2023, 15:e48011. 10.7759\/cureus.48011","journal-title":"Cureus"},{"key":"ref17","article-title":"24-hour maxillofacial administration of levodopa in a Parkinson\u2019s patient\u2014an alternative route of administration in Parkinson\u2019s disease","volume":"39","author":"Thirunavukarasu S","year":"2024","unstructured":"Thirunavukarasu S, Ramanan B, Varadharaj V, Suresh TS, Verma KV, Janardhanan HAJ, Ur AUR. 24-hour maxillofacial administration of levodopa in a Parkinson\u2019s patient\u2014an alternative route of administration in Parkinson\u2019s disease. Mov Disord. 2024, 39:","journal-title":"Mov Disord"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.103916","article-title":"First-in-human randomized controlled pilot trial of a maxillofacial drug delivery platform for low-dose systemic delivery","volume":"18","author":"Ramachandran S","year":"2026","unstructured":"Ramachandran S, Kandasamy R, Verma K, et al.. First-in-human randomized controlled pilot trial of a maxillofacial drug delivery platform for low-dose systemic delivery. Cureus. 2026, 18:e103916. 10.7759\/cureus.103916","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.10.006","article-title":"Minimal clinically important difference on the motor examination part of MDS-UPDRS","volume":"21","author":"Horv\u00e1th K","year":"2015","unstructured":"Horv\u00e1th K, Aschermann Z, \u00c1cs P, et al.. Minimal clinically important difference on the motor examination part of MDS-UPDRS. Parkinsonism Relat Disord. 2015, 21:1421-6. 10.1016\/j.parkreldis.2015.10.006","journal-title":"Parkinsonism Relat Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26479","article-title":"Bridging the gap between statistical significance and clinical relevance: a systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research","volume":"10","author":"Mishra B","year":"2024","unstructured":"Mishra B, Sudheer P, Rajan R, Agarwal A, Srivastava MV, Nilima N, Vishnu VY. Bridging the gap between statistical significance and clinical relevance: a systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research. Heliyon. 2024, 10:e26479. 10.1016\/j.heliyon.2024.e26479","journal-title":"Heliyon"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5728-8","article-title":"Pharmacokinetics of levodopa","volume":"257","author":"Contin M","year":"2010","unstructured":"Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol. 2010, 257:S253-61. 10.1007\/s00415-010-5728-8","journal-title":"J Neurol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199529040-00004","article-title":"Concentration-effect relationship of levodopa in patients with Parkinson's disease","volume":"29","author":"Harder S","year":"1995","unstructured":"Harder S, Baas H, Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin Pharmacokinet. 1995, 29:243-56. 10.2165\/00003088-199529040-00004","journal-title":"Clin Pharmacokinet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198904000-00002","article-title":"Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet","volume":"12","author":"Nelson MV","year":"1989","unstructured":"Nelson MV, Berchou RC, Lewitt PA, Kareti D, Kesaree N, Schlick P, Galloway MP. Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. Clin Neuropharmacol. 1989, 12:91-7. 10.1097\/00002826-198904000-00002","journal-title":"Clin Neuropharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220415","article-title":"On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics","volume":"22","author":"Nutt JG","year":"1987","unstructured":"Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol. 1987, 22:535-40. 10.1002\/ana.410220415","journal-title":"Ann Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.36.6.739","article-title":"Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients","volume":"36","author":"Nutt JG","year":"1986","unstructured":"Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology. 1986, 36:739-44. 10.1212\/wnl.36.6.739","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/468824-controlled-maxillofacial-administration-of-levodopa-in-a-patient-with-parkinsons-disease-a-first-in-human-24-hour-follow-up-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:25:58Z","timestamp":1776756358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/468824-controlled-maxillofacial-administration-of-levodopa-in-a-patient-with-parkinsons-disease-a-first-in-human-24-hour-follow-up-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.107436","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}